Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOVUE-128 vs ANDROID 10
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isovue-128 (iopamidol) is a nonionic, water-soluble, radiographic contrast medium that enhances imaging by attenuating X-rays, thereby increasing contrast between vascular structures and surrounding tissues. Its mechanism is based on the high iodine content which absorbs X-rays, allowing visualization of blood vessels and organs during angiography, urography, and CT scans.
Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.
Intravascular use for computed tomography (CT) imaging,Intravenous urography,Intra-arterial angiography (including coronary, peripheral, and cerebral),Ventriculography,Myelography (subarachnoid injection for spinal imaging),Off-label: Arthrography, hysterosalpingography (though not FDA-approved for these)
Male hypogonadism (primary and hypogonadotropic),Delayed puberty in males,Off-label: Androgen replacement in transgender men (masculinizing hormone therapy)
Adult: 50-200 m L (0.5-2.0 m L/kg) intravenously, single dose for contrast-enhanced CT; for angiography, dose and rate vary by procedure.
Testosterone undecanoate 750 mg (3 m L) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function; prolonged in renal impairment (up to 8-10 hours with GFR <30 m L/min).
8 hours; clinical context: steady-state achieved in 2-3 days, dosing interval 8-12 hours.
Iopamidol is not metabolized and is excreted unchanged almost entirely by the kidneys via glomerular filtration. No hepatic metabolism or significant protein binding occurs.
Hepatic metabolism via CYP3A4; undergoes extensive first-pass metabolism; metabolites primarily excreted renally.
Renal: >95% excreted unchanged in urine via glomerular filtration; fecal/biliary: <5%.
Renal: 90% as glucuronide and sulfate conjugates, 6% as unchanged drug; fecal: 4%.
Minimal protein binding (<5%), primarily to albumin.
97-99% bound primarily to sex hormone-binding globulin (SHBG) and albumin.
Approximately 0.2-0.3 L/kg, reflecting distribution into extracellular fluid.
0.5-1.0 L/kg; indicates extensive distribution into tissues and organs.
Not applicable for oral route (no oral formulation); 100% bioavailability via intravenous or intra-arterial administration.
Oral: low (variable, ~5-20% due to first-pass metabolism); intramuscular: 100%.
GFR <30 m L/min: use lowest feasible dose; GFR <15 m L/min: avoid use unless essential; consider hydration and N-acetylcysteine.
No specific dose adjustment required for renal impairment; monitor serum testosterone levels and clinical response. For severe renal impairment (GFR <30 m L/min), consider increased monitoring due to potential fluid retention.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to risk of contrast-induced nephropathy.
Contraindicated in patients with severe hepatic dysfunction (Child-Pugh class C). For mild to moderate impairment (Child-Pugh class A or B), use with caution and consider dose reduction; monitor liver function tests regularly.
Neonates: 0.5-1 m L/kg IV; Infants/Children: 1-2 m L/kg IV (max 125 m L per dose) for contrast-enhanced CT.
Not recommended for use in children; safety and efficacy not established. For delayed puberty in adolescent males: testosterone enanthate 50-200 mg intramuscularly every 2-4 weeks, titrated to response, with monitoring of bone age.
Reduce dose to lowest effective (e.g., 50-100 m L); ensure adequate hydration; monitor renal function pre and post administration.
Start at low end of dosing range (e.g., testosterone cypionate 50 mg intramuscularly every 4 weeks or gel 25 mg daily) due to potential increased sensitivity and risk of prostatic hypertrophy or cardiovascular events. Monitor serum testosterone, hematocrit, and prostate-specific antigen (PSA).
Iodinated contrast media including iopamidol are associated with an increased risk of contrast-induced acute kidney injury (CI-AKI) in patients with pre-existing renal impairment, particularly those with diabetes, volume depletion, or concurrent use of nephrotoxic drugs. Strict adherence to hydration protocols and renal monitoring is required.
None
Risk of contrast-induced nephropathy (CIN): Monitor renal function before and after administration, ensure adequate hydration, and avoid concurrent nephrotoxic agents.,Severe hypersensitivity reactions (e.g., anaphylaxis, bronchospasm): Have resuscitation equipment available; premedication may be considered for patients with known contrast allergy.,Thyroid dysfunction: Iodinated contrast may induce hyperthyroidism or hypothyroidism; caution in patients with thyroid disease.,Cardiovascular events: In patients with heart failure, coronary artery disease, or pulmonary hypertension, contrast media can cause hemodynamic instability, arrhythmias, or myocardial ischemia.,Neurologic effects: Intrathecal administration may cause seizures, arachnoiditis, or aseptic meningitis; use lowest possible dose and monitor for neurotoxicity.,Extravasation: Risk of tissue necrosis; administer through a secure IV line and monitor injection site.
Risk of hepatotoxicity; use with caution in patients with liver disease. Monitor liver function, lipid profile, and prostate-specific antigen (PSA). May cause fluid retention, gynecomastia, priapism, and sleep apnea. Not for use in women who are pregnant or breastfeeding. May accelerate growth of prostate cancer and benign prostatic hyperplasia. Androgenic effects may cause virilization in women.
Absolute: Known hypersensitivity to iopamidol, other iodine-containing contrast media, or any component of the formulation.,Absolute: Intrathecal administration in patients with significant thrombophlebitis or infection at the injection site.,Relative: Pre-existing renal impairment (e GFR <30 m L/min/1.73m²) unless benefits outweigh risks; consider alternative imaging.,Relative: Multiple myeloma, pheochromocytoma, sickle cell disease (due to risk of vaso-occlusive events).,Relative: Pregnancy (especially first trimester) unless essential for diagnosis.
Men with carcinoma of the prostate or breast; history of hypersensitivity to testosterone or any component; women who are pregnant or may become pregnant (risk of fetal harm); patients with severe hepatic or cardiac disease.
No specific food interactions. However, patients are often advised to maintain adequate hydration. Avoid alcohol consumption for 24 hours before and after the procedure as it may increase risk of dehydration. No dietary restrictions required.
No known food interactions. However, methyltestosterone can increase appetite and cause weight gain; a balanced diet is recommended.
Iodinated contrast agents, including iopamidol (ISOVUE-128), are generally considered low risk for teratogenicity in humans based on limited data. In the first trimester, there is a theoretical risk of fetal hypothyroidism due to free iodide, but clinical evidence does not show a significant increase in congenital anomalies. Second and third trimester exposure is associated with transient neonatal hypothyroidism if the agent crosses the placenta, but no structural teratogenic effects are documented. The FDA assigns a Pregnancy Category B for iodinated contrast agents.
Android 10 is a combination of methyltestosterone and ethinyl estradiol. Methyltestosterone is an androgen; exposure during pregnancy, particularly during the first trimester, can cause virilization of the female fetus. Ethinyl estradiol is contraindicated in pregnancy due to risk of fetal harm. Use is contraindicated in all trimesters.
Iopamidol is excreted into breast milk in very small amounts. The milk-to-plasma (M/P) ratio is approximately 0.04–0.08 based on limited studies. The absolute dose received by a nursing infant is estimated to be less than 0.01% of the maternal dose, which is clinically insignificant. Therefore, breastfeeding can be continued without interruption, although some experts suggest discarding milk for 24 hours post-administration as a precaution. No adverse effects on the infant have been reported.
Methyltestosterone and ethinyl estradiol are excreted in breast milk. Methyltestosterone may cause virilization in female infants. Ethinyl estradiol may reduce milk production and quality. M/P ratio not available. Breastfeeding is contraindicated.
No dosing adjustments are required for iopamidol (ISOVUE-128) during pregnancy based on pharmacokinetic changes. However, because physiological changes in pregnancy (increased plasma volume, increased renal clearance) may affect contrast agent distribution and elimination, the standard dose should be used based on body weight and indication. The lowest effective dose should be administered to minimize fetal exposure. No specific dose modifications are recommended in guidelines.
Contraindicated in pregnancy; no dosing adjustments apply. If inadvertent use occurs, discontinue immediately.
ISOVUE-128 (iopamidol) is a nonionic, low-osmolality contrast medium. Pre-warming to body temperature reduces viscosity and improves patient tolerance. Risk of contrast-induced nephropathy (CIN) increases with pre-existing renal impairment; assess renal function (e GFR) prior to administration. Adequate hydration is critical. Monitor for delayed hypersensitivity reactions (up to 7 days). Metformin should be withheld for 48 hours post procedure if renal function is compromised. Have emergency equipment available for anaphylactoid reactions.
Android 10 is a brand name for methyltestosterone, an androgen and anabolic steroid. Use is restricted to replacement therapy in males with hypogonadism or delayed puberty due to androgen deficiency. Monitor liver function due to risk of peliosis hepatis and hepatocellular carcinoma. Contraindicated in males with breast or prostate cancer. Can cause erythrocytosis; monitor hematocrit. Discontinue if signs of virilization in women or priapism in men. Use caution in elderly due to increased risk of prostatic hypertrophy.
Inform your healthcare provider if you have any allergies, especially to contrast media or iodine.,Tell your provider about all medications you take, particularly metformin or any kidney-affecting drugs.,You may be asked to drink extra fluids before and after the procedure to protect your kidneys.,Report any symptoms like hives, itching, difficulty breathing, or swelling of the face/throat immediately.,If you have diabetes and take metformin, your doctor may advise stopping it for 48 hours after the scan.,Sensation of warmth, a metallic taste, or nausea during injection is common and usually resolves quickly.,After the procedure, you can resume normal diet unless directed otherwise.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report signs of liver problems: yellowing of skin or eyes, dark urine, light-colored stools, abdominal pain.,Notify your doctor if you experience swelling of ankles or feet, trouble breathing, or persistent erections lasting more than 4 hours.,May cause aggressive behavior, mood swings, or depression; contact your doctor if these occur.,Do not take if you are pregnant or breastfeeding.,Keep all appointments for blood tests and liver function monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOVUE-128 vs ANDROID 10, answered by our medical review team.
ISOVUE-128 is a Contrast Media that works by Isovue-128 (iopamidol) is a nonionic, water-soluble, radiographic contrast medium that enhances imaging by attenuating X-rays, thereby increasing contrast between vascular structures and surrounding tissues. Its mechanism is based on the high iodine content which absorbs X-rays, allowing visualization of blood vessels and organs during angiography, urography, and CT scans.. ANDROID 10 is a Androgen that works by Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOVUE-128 and ANDROID 10 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOVUE-128 is: Adult: 50-200 m L (0.5-2.0 m L/kg) intravenously, single dose for contrast-enhanced CT; for angiography, dose and rate vary by procedure.. The standard adult dose of ANDROID 10 is: Testosterone undecanoate 750 mg (3 m L) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOVUE-128 and ANDROID 10 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOVUE-128 is classified as Category C. Iodinated contrast agents, including iopamidol (ISOVUE-128), are generally considered low risk for teratogenicity in humans based on limited data. In the first trimester, there is . ANDROID 10 is classified as Category C. Android 10 is a combination of methyltestosterone and ethinyl estradiol. Methyltestosterone is an androgen; exposure during pregnancy, particularly during the first trimester, can . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.